Good morning, you're tuned into Markets Desk.
Oil markets took a decisive leg lower Monday after the United States and Iran agreed to a sixty-day ceasefire framework, with West Texas Intermediate and Brent crude both retreating as traders unwound geopolitical risk premiums that had been baked in for weeks. The deal removes a meaningful supply disruption threat from the table.
Gold, meanwhile, is telling a nuanced story. Prices climbed to a one-week high on the back of that same Iran news, which sounds counterintuitive until you consider the reasoning — easing tensions reduce inflationary pressure and diminish the case for aggressive rate hikes, making non-yielding assets like gold more attractive on a relative basis.
Shifting to pharma, Bayer scored a meaningful regulatory win today as the FDA approved AMBELVIST, its next-generation gadolinium-based contrast agent for use in contrast-enhanced MRI imaging. For Bayer, this is a commercial foothold in diagnostic imaging at a time the company badly needs positive catalysts, having faced significant legal and financial headwinds over the past several years. Expect analysts to revisit near-term revenue projections on the back of this.
That's the tape. Markets Desk, signing off the floor.
